Board
The Board is the steering and executive body which advises the General Assembly on new activities and formulates proposals to be ratified by the General Assembly. The Board meets at least twice a year. The Board consists of elected (voting) members and several ex officio members. The Board members select among themselves the President, Vice-President, Treasurer, and Secretary General.
Full members (voting)
-
-
Past President
Jean-Yves Blay
Lyon, France
-
Vice-President
Vincent Grégoire
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Secretary General
Patrick Schöffski
Leuven, Belgium
-
Treasurer
Martin van den Bent
Rotterdam, Netherlands
Chairs
-
Clinical Research Division (CRD)
Bertrand Tombal
Brussels, Belgium
-
Translational Research Division (TRD)
Christian Dittrich
Kaiser Franz Josef Spital
Vienna, Austria
-
Membership Committee (MC)
Mogens Gronvold
Bispebjerg Hospital
Copenhagen, Denmark
-
New Drug Advisory Committee (NDAC)
Jean-Pierre Bizzari
Celgene
Haveford, United States
-
Protocol Review Committee (PRC)
Frances Shepherd
University Health Network - Oci / Princess Margaret Hospital
Toronto, Canada
-
Quality Assurance Committee
Lisa Licitra
Istituto Nazionale per lo Studio a la Cura dei Tumori
Milano, Italy
-
Scientific Audit Committee (SAC)
Elizabeth Eisenhauer
Kingston Regional Cancer Center
Kingston, Canada
-
Translational Research Advisory Committee (TRAC)
Sabine Tejpar
U.Z. Leuven
Leuven, Belgium
Members
-
/
Serge Evrard
Institut Bergonie
Bordeaux, France
-
/
Winette van der Graaf
The Institute of Cancer Research: Royal Cancer Hospital
London, United Kingdom
Ex officio members (non voting)
-
Director Special Projects; EORTC
Françoise Meunier
Bruxelles, Belgium
-
Chair, EORTC Cancer Research Fund
Diego Du Monceau
Brussels, Belgium
-
Editor-in-Chief, European Journal of Cancer
Alexander M. Eggermont
Rotterdam, Netherlands
-
European Journal of Cancer Liaison Officer
Jean-Claude Horiot
Dijon, France